Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for prevention and reduction of delayed graft function after kidney transplantation
ChiCTR2600117992Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delayed graft function (DGF) and end-stage kidney disease (ESKD) comparing ravulizumab with placebo (2 arms). Primary endpoint: Time to freedom from dialysis through 90 days post-transplant. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ravulizumab
03
Conditions
delayed graft function (DGF)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2600117992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117992.